Evidence map›Paper›PMID 39751983›Full record

Trial reportAnnals of surgical oncology2025

Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or Ductal Carcinoma In Situ in Patients Diagnosed with Flat Epithelial Atypia by Core Needle Biopsy (TBCRC 034).

Faina Nakhlis, Gabrielle M Baker, Tianyu Li, Priscilla F McAuliffe, George Plitas, Kandice K Ludwig, Marc Boisvert, Laura H Rosenberger, Kristalyn K Gallagher, Lisa Jacobs and 8 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Faina NakhlisDivision of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. fnakhlis1@bwh.harvard.edu.ORCID http://orcid.org/0000-0003-4752-0161
Gabrielle M BakerHarvard Medical School, Boston, MA, USA.
Tianyu LiDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Priscilla F McAuliffeUPMC Hillman Cancer Center, Pittsburgh, PA, USA.
George PlitasBreast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kandice K LudwigIndiana University Cancer Center, Indianapolis, IN, USA.
Marc BoisvertGeorgetown University Cancer Center, Washington, DC, USA.
Laura H RosenbergerDuke University Medical Center, Durham, NC, USA.
Kristalyn K GallagherUniversity of North Carolina, Chapel Hill, NC, USA.
Lisa JacobsJohns Hopkins University, Baltimore, MD, USA.
Suniti N NimbkarDivision of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Sheldon FeldmanMontefiore Medical Center, New York, NY, USA.
Paulina LangeDivision of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Victoria AttayaDivision of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Michelle DeMeoDivision of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Ashton FraettarelliDivision of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Stuart J SchnittBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Tari A KingDivision of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFlat epithelial atypia (FEA), a rare breast proliferative lesion, is often diagnosed following core biopsy (CB) of mammographic microcalcifications. In the prospective multi-institution TBCRC 034 trial, we investigate the upgrade rate to ductal carcinoma in situ (DCIS) or invasive cancer following excision for patients diagnosed with FEA on CB. PATIENTS AND

methodsPatients with a breast imaging reporting and data system (BI-RADS) ≤ 4 imaging abnormality and a concordant CB diagnosis of FEA were identified for excision. Upgrade rates were determined on the basis of local and central pathology review. The prespecified threshold to omit excision of FEA on CB was an upgrade rate of ≤ 3%. Sample size and confidence intervals were based on exact binomial calculation.

resultsOverall, 129 patients underwent excision (median age 50 years, range 30-84 years). After local pathology review, 6/129 patients (4.7%; 95% CI 1.7-9.8%) were upgraded to invasive carcinoma (n = 3) or DCIS (n = 3) at excision. Among 116 patients with CB available for central pathology review, FEA was confirmed in 78 (67.2%, 95% CI 57.9-75.7%). Of these, only one patient was upgraded to DCIS (1.3%; 95% CI 0.03-6.9%), which was also one of the locally upgraded cases. Among the other five local upgrades, two did not have CB available for central review, two CB had ADH, and one CB had normal tissue on central review.

conclusionsAmong patients with FEA on CB, the upgrade rate was 4.7% based on local pathology review and 1.3% based on central pathology review. These findings highlight the importance of shared decision-making in the management of FEA.

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingNeoplasms, Multiple PrimaryAdultAgedAged, 80 and overBiopsy, Large-Core NeedleFemaleFollow-Up StudiesHumansIncidenceMammographyMiddle AgedNeoplasm InvasivenessPrognosisCore biopsyDuctal carcinoma in situFlat epithelial atypiaInvasive breast cancerUpgrade rate

Identifiers

PMID39751983

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.